CardiologyOnline.net

Cardiology Xagena

The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


The comparative safety of Dabigatran ( Pradaxa ) versus Warfarin ( Coumadin ) for treatment of non-valvular atrial fibrillation in general practice settings has not been established. Researchers fo ...


A study has assessed safety and cardiovascular outcomes of Dronedarone ( Multaq ) in patients with paroxysmal or persistent atrial fibrillation ( AF ) with coronary heart disease ( CHD ). Coronary h ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


Outcome data are limited on aortic valve replacement ( AVR ) in nonagenarian patients. This study reports the experience at Mayo Clinic ( Rochester, Minnesota, USA ) in the treatment of this elderly p ...


The myocardial effects of phosphodiesterase type 5 inhibitors ( PDE5i ) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. Resear ...


Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The American Association for Thoracic Surgery ( AATS ) has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation ( POAF ) and f ...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system ( RAAS ) blockade with angiotensin-converting-enzyme inhibit ...


Ventricular fibrillation is one of the most serious complications of acute myocardial infarction, with a high mortality rate. There is a lack of value of rescue thrombolysis in ST-segment elevation my ...


Despite endorsement of Digoxin in clinical practice guidelines, there exist limited data on its safety in atrial fibrillation / atrial flutter. The goal of a study was to evaluate the association o ...


Post-thrombotic syndrome ( PTS ) is a common and burdensome complication of deep venous thrombosis ( DVT ). Previous trials suggesting benefit of elastic compression stockings ( ECS ) to prevent post- ...


Body-mass index ( BMI ) and diabetes mellitus have increased worldwide, whereas global average blood pressure and cholesterol have decreased or remained unchanged in the past three decades. Research ...


The outcome of patients with ruptured abdominal aortic aneurysm ( rAAA ) varies by country. Study of practice differences might allow the formulation of pathways to improve care. Data from the Hosp ...


Four new oral anticoagulants compare favourably with Warfarin ( Coumadin ) for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups nee ...


LCZ696 has shown to be superior to Ace inhibitor Enalapril ( Enapren ) on key endpoints in the largest heart failure study ever done. In PARADIGM-HF patients with heart failure with reduced ejection f ...


Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. Serelaxin is a synthetic versi ...


Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan. The findin ...


Renal denervation ( RDN ) with radiofrequency ablation substantially reduces blood pressure in patients with treatment-resistant hypertension. Researchers have assessed the long-term antihypertensive ...


In final draft guidance NICE ( National Institute for Health and Care Excellence ) has defined which heart devices ( known as implantable cardiac devices ) are the most clinically and cost effective. ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati